Literature DB >> 35920191

Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand.

Nasamon Wanlapakorn1, Nungruthai Suntronwong1, Sitthichai Kanokudom1, Suvichada Assawakosri1, Pornjarim Nilyanimit1, Ritthideach Yorsaeng1, Jira Chansaenroj1, Yong Poovorawan1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35920191      PMCID： PMC9518238          DOI： 10.1080/20477724.2022.2108646

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN： 2047-7724            Impact factor:   3.735


× No keyword cloud information.
  8 in total

1.  Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.

Authors:  Suvichada Assawakosri; Sitthichai Kanokudom; Jira Chansaenroj; Nungruthai Suntronwong; Chompoonut Auphimai; Pornjarim Nilyanimit; Preeyaporn Vichaiwattana; Thanunrat Thongmee; Thaneeya Duangchinda; Warangkana Chantima; Pattarakul Pakchotanon; Donchida Srimuan; Thaksaporn Thatsanatorn; Sirapa Klinfueng; Natthinee Sudhinaraset; Juthathip Mongkolsapaya; Nasamon Wanlapakorn; Sittisak Honsawek; Yong Poovorawan
Journal:  Int J Infect Dis       Date:  2022-07-19       Impact factor: 12.074

2.  Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.

Authors:  Alejandro Jara; Eduardo A Undurraga; José R Zubizarreta; Cecilia González; Alejandra Pizarro; Johanna Acevedo; Katherinne Leo; Fabio Paredes; Tomás Bralic; Verónica Vergara; Marcelo Mosso; Francisco Leon; Ignacio Parot; Paulina Leighton; Pamela Suárez; Juan Carlos Rios; Heriberto García-Escorza; Rafael Araos
Journal:  Lancet Glob Health       Date:  2022-04-23       Impact factor: 38.927

3.  Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.

Authors:  Suvichada Assawakosri; Sitthichai Kanokudom; Nungruthai Suntronwong; Chompoonut Auphimai; Pornjarim Nilyanimit; Preeyaporn Vichaiwattana; Thanunrat Thongmee; Thaneeya Duangchinda; Warangkana Chantima; Pattarakul Pakchotanon; Donchida Srimuan; Thaksaporn Thatsanatorn; Sirapa Klinfueng; Ritthideach Yorsaeng; Natthinee Sudhinaraset; Nasamon Wanlapakorn; Juthathip Mongkolsapaya; Sittisak Honsawek; Yong Poovorawan
Journal:  J Infect Dis       Date:  2022-10-17       Impact factor: 7.759

4.  Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.

Authors:  Emma K Accorsi; Amadea Britton; Katherine E Fleming-Dutra; Zachary R Smith; Nong Shang; Gordana Derado; Joseph Miller; Stephanie J Schrag; Jennifer R Verani
Journal:  JAMA       Date:  2022-02-15       Impact factor: 157.335

5.  Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.

Authors:  Nasamon Wanlapakorn; Nungruthai Suntronwong; Harit Phowatthanasathian; Ritthideach Yorsaeng; Thanunrat Thongmee; Preeyaporn Vichaiwattana; Chompoonut Auphimai; Lakkhana Wongsrisang; Sirapa Klinfueng; Natthinee Sudhinaraset; Yong Poovorawan
Journal:  Vaccine       Date:  2022-04-18       Impact factor: 4.169

6.  Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.

Authors:  Jira Chansaenroj; Nungruthai Suntronwong; Sitthichai Kanokudom; Suvichada Assawakosri; Ritthideach Yorsaeng; Preeyaporn Vichaiwattana; Sirapa Klinfueng; Lakana Wongsrisang; Donchida Srimuan; Thaksaporn Thatsanatorn; Thanunrat Thongmee; Chompoonut Auphimai; Pornjarim Nilyanimit; Nasamon Wanlapakorn; Natthinee Sudhinaraset; Yong Poovorawan
Journal:  Vaccines (Basel)       Date:  2022-07-03

7.  Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.

Authors:  Nungruthai Suntronwong; Sitthichai Kanokudom; Chompoonut Auphimai; Suvichada Assawakosri; Thanunrat Thongmee; Preeyaporn Vichaiwattana; Thaneeya Duangchinda; Warangkana Chantima; Pattarakul Pakchotanon; Jira Chansaenroj; Jiratchaya Puenpa; Pornjarim Nilyanimit; Donchida Srimuan; Thaksaporn Thatsanatorn; Natthinee Sudhinaraset; Nasamon Wanlapakorn; Juthathip Mongkolsapaya; Yong Poovorawan
Journal:  J Med Virol       Date:  2022-08-10       Impact factor: 20.693

8.  Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.

Authors:  Nick Andrews; Julia Stowe; Freja Kirsebom; Samuel Toffa; Ruchira Sachdeva; Charlotte Gower; Mary Ramsay; Jamie Lopez Bernal
Journal:  Nat Med       Date:  2022-01-14       Impact factor: 87.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.